[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse IRAK3

Summary
SymbolIRAK3
Nameinterleukin-1 receptor-associated kinase 3
Aliases IRAK-M; ASRT5; IRAKM; IL-1 receptor-associated kinase M; IRAK-3
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00531 Death domain
PF00069 Protein kinase domain
Function

Inhibits dissociation of IRAK1 and IRAK4 from the Toll-like receptor signaling complex by either inhibiting the phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor complex.

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0001933 negative regulation of protein phosphorylation
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0001960 negative regulation of cytokine-mediated signaling pathway
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002367 cytokine production involved in immune response
GO:0002440 production of molecular mediator of immune response
GO:0002507 tolerance induction
GO:0002643 regulation of tolerance induction
GO:0002645 positive regulation of tolerance induction
GO:0002683 negative regulation of immune system process
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002701 negative regulation of production of molecular mediator of immune response
GO:0002718 regulation of cytokine production involved in immune response
GO:0002719 negative regulation of cytokine production involved in immune response
GO:0002755 MyD88-dependent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0006469 negative regulation of protein kinase activity
GO:0009615 response to virus
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0010931 macrophage tolerance induction
GO:0010932 regulation of macrophage tolerance induction
GO:0010933 positive regulation of macrophage tolerance induction
GO:0010934 macrophage cytokine production
GO:0010935 regulation of macrophage cytokine production
GO:0010936 negative regulation of macrophage cytokine production
GO:0031348 negative regulation of defense response
GO:0031349 positive regulation of defense response
GO:0032088 negative regulation of NF-kappaB transcription factor activity
GO:0032494 response to peptidoglycan
GO:0032496 response to lipopolysaccharide
GO:0032615 interleukin-12 production
GO:0032635 interleukin-6 production
GO:0032640 tumor necrosis factor production
GO:0032655 regulation of interleukin-12 production
GO:0032675 regulation of interleukin-6 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032695 negative regulation of interleukin-12 production
GO:0032715 negative regulation of interleukin-6 production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0032984 macromolecular complex disassembly
GO:0033673 negative regulation of kinase activity
GO:0034121 regulation of toll-like receptor signaling pathway
GO:0034122 negative regulation of toll-like receptor signaling pathway
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0042326 negative regulation of phosphorylation
GO:0043241 protein complex disassembly
GO:0043242 negative regulation of protein complex disassembly
GO:0043244 regulation of protein complex disassembly
GO:0043330 response to exogenous dsRNA
GO:0043331 response to dsRNA
GO:0043405 regulation of MAP kinase activity
GO:0043407 negative regulation of MAP kinase activity
GO:0043409 negative regulation of MAPK cascade
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045824 negative regulation of innate immune response
GO:0046777 protein autophosphorylation
GO:0050777 negative regulation of immune response
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051348 negative regulation of transferase activity
GO:0060759 regulation of response to cytokine stimulus
GO:0060761 negative regulation of response to cytokine stimulus
GO:0061082 myeloid leukocyte cytokine production
GO:0070498 interleukin-1-mediated signaling pathway
GO:0070555 response to interleukin-1
GO:0071347 cellular response to interleukin-1
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:1902532 negative regulation of intracellular signal transduction
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
Molecular Function GO:0000287 magnesium ion binding
GO:0004674 protein serine/threonine kinase activity
GO:0046982 protein heterodimerization activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04722 Neurotrophin signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-446652: Interleukin-1 signaling
R-HSA-166058: MyD88
R-HSA-449147: Signaling by Interleukins
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolIRAK3
Nameinterleukin-1 receptor-associated kinase 3
Aliases IRAK-M; ASRT5; IRAKM; IL-1 receptor-associated kinase M; IRAK-3
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IRAK3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolIRAK3
Nameinterleukin-1 receptor-associated kinase 3
Aliases IRAK-M; ASRT5; IRAKM; IL-1 receptor-associated kinase M; IRAK-3
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IRAK3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolIRAK3
Nameinterleukin-1 receptor-associated kinase 3
Aliases IRAK-M; ASRT5; IRAKM; IL-1 receptor-associated kinase M; IRAK-3
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IRAK3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2150.569
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.530.504
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0150.982
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5270.295
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.5010.373
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7010.735
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5450.31
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1410.382
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0460.973
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5410.357
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3060.0831
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4980.00142
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IRAK3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIRAK3
Nameinterleukin-1 receptor-associated kinase 3
Aliases IRAK-M; ASRT5; IRAKM; IL-1 receptor-associated kinase M; IRAK-3
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IRAK3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIRAK3
Nameinterleukin-1 receptor-associated kinase 3
Aliases IRAK-M; ASRT5; IRAKM; IL-1 receptor-associated kinase M; IRAK-3
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IRAK3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IRAK3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIRAK3
Nameinterleukin-1 receptor-associated kinase 3
Aliases IRAK-M; ASRT5; IRAKM; IL-1 receptor-associated kinase M; IRAK-3
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IRAK3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIRAK3
Nameinterleukin-1 receptor-associated kinase 3
Aliases IRAK-M; ASRT5; IRAKM; IL-1 receptor-associated kinase M; IRAK-3
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IRAK3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIRAK3
Nameinterleukin-1 receptor-associated kinase 3
Aliases IRAK-M; ASRT5; IRAKM; IL-1 receptor-associated kinase M; IRAK-3
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IRAK3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIRAK3
Nameinterleukin-1 receptor-associated kinase 3
Aliases IRAK-M; ASRT5; IRAKM; IL-1 receptor-associated kinase M; IRAK-3
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IRAK3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.